Open App →
Back to News Feed
Korea Times November 4, 2026 By gyulee@koreatimes.co.kr(KoreaTimes) negative

Gaon Cable expands US production capacity amid rising tariffs

AI / LLMManufacturingSupply ChainRegulationData Center
Gaon Cable, a subsidiary of LS Cable & System, is gaining a competitive edge in the United States as Washington tightens tariffs on steel, aluminum and copper-related products, with its local manufacturing base helping it reduce tariff exposure and navigate supply chain uncertainties. The company is expanding its U.S. production capacity while broadening its business from artificial intelligence (AI) data centers to power transmission networks and power plants, positioning itself to tap growing demand for electricity infrastructure. Gaon Cable operates LSCUS, its U.S. production subsidiary, in Tarboro, North Carolina. It supplies power cables and bus ducts to global technology giants and AI cloud service providers, strengthening its foothold in the North American market. The company plans to invest approximately $50 million to add two production lines at its Tarboro facility, doubling its cable production capacity by 2027. Further expansion is under consideration depending on new orders and customers' investment plans. LSCUS' revenue is projected to rise from approximately 440 billion wo
Read original article ↗

Related Articles

Integrated Storage Empowering Edge AI | Longsys präsentiert sich auf der electronica 2026

MÜNCHEN, 4. November 2026 /PRNewswire/ -- Die electronica 2026 findet vom 10. bis 13. November in München statt. Da sich

PR Newswire · November 4, 2026

GigaDevice sees tight niche DRAM supply, slower price gains

AI demand continues to heat up while major global memory makers shift capacity toward higher-value products, keeping nic

Digitimes · November 4, 2026

Decoy processors carry Korean HBM past US export controls into China

A loophole in US export controls reportedly lets high-bandwidth memory (HBM) made by Samsung Electronics and SK Hynix re

Digitimes · November 4, 2026

HLB liver cancer drug enters FDA review, decision expected by April

Korean biopharmaceutical group HLB is getting a second shot at U.S. Food and Drug Administration (FDA) approval for its

Korea Times · November 4, 2026